Novo Nordisk CEO Says the Drugmaker Is More Active than Ever in Seeking Out Deals

Why It Matters

Accelerated M&A and pipeline expansion can help Novo sustain growth and defend market share amid rising competition in the lucrative obesity‑treatment space. Successful deals would deepen its product portfolio, supporting revenue diversification and shareholder value.

Key Takeaways

• Novo plans accelerated M&A to broaden obesity‑drug pipeline.
• CagriSema targets GLP‑1 and amylin, expected approval year‑end.
• Zenagamtide, an amylin drug, moves into fast‑track development.
• Wegovy pill beats forecasts, prompting higher profit guidance.
• Eli Lilly now leads weekly GLP‑1 shot market share.

Pulse Analysis

Novo Nordisk, the Danish pioneer behind Ozempic and Wegovy, has long dominated the GLP‑1 segment of the obesity‑treatment market. Yet recent data show Eli Lilly overtaking Novo in weekly injectable GLP‑1 sales, a shift that has prompted analysts to question the sustainability of Novo’s lead. The company’s latest quarterly results, however, revealed stronger‑than‑expected performance for its oral Wegovy formulation, prompting an upward revision of full‑year profit guidance. This mixed signal underscores the pressure on Novo to reinforce its pipeline while defending market share.

Doustdar’s comments signal a strategic pivot toward external growth, with the CEO promising “more deals” to capture complementary assets. Novo’s pipeline currently showcases CagriSema, a dual GLP‑1/amylin agonist slated for regulatory review by year‑end, and zenagamtide, an experimental amylin‑focused molecule now on an accelerated development track. Both candidates aim to broaden therapeutic options beyond injectable shots, tapping into the burgeoning demand for oral obesity treatments. Industry observers note that such assets are attractive acquisition targets for rivals seeking to fill gaps in their own GLP‑1 portfolios.

The heightened M&A focus could reshape the competitive landscape, as Novo seeks to lock in next‑generation molecules before rivals can secure them. For shareholders, the combination of a stronger oral product line and potential bolt‑on acquisitions offers a dual pathway to revenue growth, mitigating the risk of losing ground to Eli Lilly’s expanding injectable franchise. Analysts will watch deal activity closely, assessing whether Novo can translate pipeline optimism into tangible market share gains and sustain its premium‑pricing power in a crowded obesity‑therapy market.